Biotech firm Resother is well on the way to clinical trials - lands DKK 16 million

Resother Pharma, which is developing a new type of anti-inflammatory medicine, has secured DKK 16 million (USD 2.4 million) - enough to take the company's first drug to clinical trials.

Lone Veng, CEO of Resother Pharma Photo: Photo: Resother Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles